Optimal medical treatment of cardiovascular risk factors: can we prevent the development of heart failure? (Q37390750)

20 August 2017

1 reference

title

Optimal medical treatment of cardiovascular risk factors: can we prevent the development of heart failure? (English)

1 reference

20 August 2017

0 references

Ana C Alba

1

1 reference

PubMed ID

19210211

20 August 2017

Diego H Delgado

series ordinal

2

1 reference

20 August 2017

1 February 2009

1 reference

Expert Review of Cardiovascular Therapy

20 August 2017

1 reference

20 August 2017

7

1 reference

20 August 2017

2

1 reference

20 August 2017

147-157

1 reference

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...]

20 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

A standardized definition of ischemic cardiomyopathy for use in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Risk factors for heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Heart failure in the general population of men--morbidity, risk factors and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

CARMELA: assessment of cardiovascular risk in seven Latin American cities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

The epidemiology of heart failure: the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Epidemiology of diastolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Glycemic control and heart failure among adult patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Heart failure in diabetes and related conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Metformin use in decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Glitazones and heart failure: critical appraisal for the clinician.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Effect of ramipril on the incidence of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Prevalence and Trends in Obesity Among US Adults, 1999-2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Obesity and the risk of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE--a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Metabolic syndrome and the risk of cardiovascular disease in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Metabolic syndrome and risk for heart failure in middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

The metabolic syndrome and mortality in an ethnically diverse heart failure population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Metabolic syndrome and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Management of obesity cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Class effects of statins in elderly patients with congestive heart failure: a population-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Lessons from curbing the coronary artery disease epidemic for confronting the impending epidemic of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Lifetime Risk for Developing Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: an innocent bystander?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.2.147

21 January 2018

Identifiers

DOI

10.1586/14779072.7.2.147

1 reference

release_6mdnok43cbbhrklaqwaysifekm

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6mdnok43cbbhrklaqwaysifekm

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

19210211

1 reference

PubMed ID

19210211